Shenzhen Salubris Pharmaceuticals

002294 · SZSE · China

Public Market Listing

002294SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Shenzhen Salubris Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
0Approved
3Phase 3 / Filed
4Phase 1–2 / Early
5Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Phase 3
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Phase 3
Endothelin receptor type A (ETA)Small molecule
HypertensionChronic Kidney Disease
Phase 2
HER3 × ErbB4Biologic (subtype unspecified)
Heart Failure
Phase 2
Apolipoprotein(a) [apo(a)] / apo(a)-apoB100 interactionSmall molecule
Atherosclerotic Cardiovascular Disease
Phase 2
Aldosterone synthase (CYP11B2)Small molecule
HypertensionChronic Kidney Disease
Phase 2
GLP-1 receptorSmall molecule
Type 2 Diabetes

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
SAL0137Phase 2Elevated Lipoprotein(a)
Est. primary completion 2026-12-12 · NCT07729475 · CT.gov ↗
What to watch
2027 (4)
March 2027 (1)
SAL0140Phase 2Uncontrolled Hypertension
Est. primary completion 2027-03-01 · NCT07654140 · CT.gov ↗
What to watch
April 2027 (1)
SAL0140Phase 2Primary Aldosteronism
Est. primary completion 2027-04-01 · NCT07646535 · CT.gov ↗
What to watch
October 2027 (1)
SAL0140Phase 2Chronic Kidney Disease
Est. primary completion 2027-10-08 · NCT07647133 · CT.gov ↗
What to watch
November 2027 (1)
SAL0150Phase 2Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM
Est. primary completion 2027-11-30 · NCT07923357 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

11 May 2026Topline resultJK07RENEU-HF Phase 2 (NCT06369298) 26-week interim: LVEF improved in every dose group vs placebo but not statistically significant; KCCQ improved
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Source ↗
September 2025Filing acceptedSAL003NMPA accepts the BLA for SAL003 (anti-PCSK9 antibody) in hypercholesterolemia
CN, NMPA · Shenzhen Salubris Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$177M$19M$157M—report ↗
View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$453M$51M$139M—report ↗
2025-H1$294M$32M$120M—report ↗
2025-Q1$146M$15M$196M—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$606M$75M$138M—report ↗

Shenzhen Salubris Pharmaceuticals reported revenue of $605.98M for fiscal 2025, up 8.5% YoY, with R&D spend of $75.09M, up 28.1% YoY. Cash and equivalents stood at $138.33M. Net income or loss and quarterly net burn were not disclosed, and no analyst consensus comparison was provided.

The company disclosed that its innovative siRNA drug SAL0195 received clinical trial approval for a lipoprotein-related indication, and that its sacubitril/alisartan/amlodipine tablet had a marketing application accepted for review. No forward-looking guidance was stated in the material.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$558M$59M$154M—report ↗
2023-FY$476M$58M$186M—report ↗
2022-FY$519M$79M$384M—report ↗
2021-FY$474M$55M$508M—report ↗